Amgen Trading 10.5% Above Intrinsic Value Amid Dividend Growth
Amgen Inc (NASDAQ: AMGN) reported encouraging but preliminary results from its Phase 3 trial of dazodalibep for systemic Sjogren's syndrome. The treatment showed potential clinical risk reductions, according to Citi. However, the firm maintains a Neutral rating with a $405 price target pending more detailed data.
The company offers a dividend yield of 2.44% with a moderate payout ratio of 44%, supported by a 3-year dividend growth rate of 7.1%. Amgen's GF Value suggests the stock is fairly valued but currently about 10.5% over its intrinsic value estimate, indicating a 'Fairly Valued' label.
The company's GF Score stands at a robust 86/100, reflecting strong profitability and growth fundamentals despite some financial strength concerns. However, recent insider activity reveals no insider buying and $29.3 million in insider sales over the past 12 months, while 12 prominent gurus hold AMGN shares with a slight net trimming trend.
For dividend-focused investors, Amgen presents a relatively safe and attractive income opportunity supported by its moderate payout ratio and steady dividend growth. However, the mixed signals from insider selling and guru trimming suggest that investors should monitor upcoming clinical trial data and financial developments closely.